Lin You-Yen, Chuang De-Maw, Chi Cheng-Yu, Hung Shih-Ya
Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan.
Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA.
Neurotherapeutics. 2025 Mar;22(2):e00501. doi: 10.1016/j.neurot.2024.e00501. Epub 2024 Nov 27.
Parkinson's disease (PD) is a prevalent movement disorder characterized by mitochondrial dysfunction and dopaminergic neuronal loss in the substantia nigra of the midbrain. Currently, there are no effective treatments to cure or slow the progression of PD, highlighting an urgent need for new therapeutic strategies. Emerging evidence suggests that mesenchymal stem cells (MSCs) and fibroblast growth factor 21 (FGF21) are potential candidates for PD treatment. This study investigates a therapeutic strategy involving FGF21 delivered via mouse MSCs in the PD model of mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and dopaminergic SH-SY5Y cells exposed to 1-methyl-4-phenylpyridinium (MPP). FGF21-overexpressing MSCs were administered intranasally, either before or after MPTP treatment in mice. Intranasally delivered FGF21-overexpressing MSCs efficiently migrated to the injured substantia nigra, ameliorated MPTP-induced PD-like motor deficits, reinstated dopaminergic neurons in the substantia nigra and nerve terminals in the striatum, as well as normalized brain-derived neurotrophic factor (BDNF) and FGF21 levels. In contrast, MSCs not overexpressing FGF21 showed limited or no impact on these parameters. In a PD cellular model of MPP-treated SH-SY5Y cells, FGF21-overexpressing MSCs showed enhanced PD cell viability. Treatment with conditioned medium from FGF21-overexpressing MSCs or exogenous FGF21 prevented cell death, reduced mitochondrial reactive oxygen species (ROS), and restored neuroprotective proteins, including phospho-Akt, BDNF, and Bcl-2. These findings indicate that intranasal delivery of FGF21-overexpressing MSCs holds promise as a potential PD therapy, likely through activating the Akt-BDNF-Bcl-2 pathway, normalizing mitochondrial dysfunction, and mitigating dopaminergic neurodegeneration. Further clinical investigations are essential to validate these promising findings.
帕金森病(PD)是一种常见的运动障碍,其特征是线粒体功能障碍和中脑黑质多巴胺能神经元丧失。目前,尚无有效的治疗方法来治愈或减缓PD的进展,这凸显了对新治疗策略的迫切需求。新出现的证据表明,间充质干细胞(MSCs)和成纤维细胞生长因子21(FGF21)是PD治疗的潜在候选者。本研究调查了一种治疗策略,该策略涉及通过小鼠MSCs递送FGF21,用于在用1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)处理的小鼠PD模型以及暴露于1-甲基-4-苯基吡啶鎓(MPP)的多巴胺能SH-SY5Y细胞中。在小鼠MPTP治疗之前或之后,经鼻给予过表达FGF21的MSCs。经鼻递送的过表达FGF21的MSCs有效地迁移至受损的黑质,改善了MPTP诱导的PD样运动缺陷,恢复了黑质中的多巴胺能神经元和纹状体中的神经末梢,以及使脑源性神经营养因子(BDNF)和FGF21水平正常化。相比之下,未过表达FGF21的MSCs对这些参数的影响有限或没有影响。在用MPP处理的SH-SY5Y细胞的PD细胞模型中,过表达FGF21的MSCs显示出增强的PD细胞活力。用过表达FGF21的MSCs的条件培养基或外源性FGF21处理可防止细胞死亡,减少线粒体活性氧(ROS),并恢复神经保护蛋白,包括磷酸化Akt、BDNF和Bcl-2。这些发现表明,经鼻递送过表达FGF21的MSCs有望成为一种潜在的PD治疗方法,可能是通过激活Akt-BDNF-Bcl-2途径、使线粒体功能障碍正常化以及减轻多巴胺能神经变性。进一步的临床研究对于验证这些有前景的发现至关重要。